Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $38,221.81 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 7,393 shares of the company’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $5.17, for a total value of $38,221.81. Following the completion of the transaction, the insider directly owned 614,887 shares in the company, valued at approximately $3,178,965.79. The trade was a 1.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenyu Xu also recently made the following trade(s):

• On Monday, April 20th, Zhenyu Xu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.21, for a total value of $3,167.68.
• On Tuesday, April 14th, Zhenyu Xu sold 600 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.97, for a total transaction of $2,982.00.
• On Monday, April 13th, Zhenyu Xu sold 4,414 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total value of $21,010.64.
• On Friday, April 10th, Zhenyu Xu sold 3,706 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.68, for a total transaction of $17,344.08.
• On Thursday, April 9th, Zhenyu Xu sold 1,936 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total value of $9,176.64.
• On Wednesday, April 8th, Zhenyu Xu sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total transaction of $13,552.00.

SOPHiA GENETICS Price Performance

NASDAQ:SOPH opened at $5.82 on Friday. SOPHiA GENETICS SA has a one year low of $2.92 and a one year high of $6.30. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. The stock has a market cap of $488.24 million, a P/E ratio of -11.19 and a beta of 0.96. The company has a fifty day moving average price of $5.16 and a 200 day moving average price of $4.98.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The firm had revenue of $21.69 million during the quarter, compared to the consensus estimate of $20.40 million.

Hedge Funds Weigh In On SOPHiA GENETICS

Several institutional investors and hedge funds have recently made changes to their positions in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after buying an additional 5,432,871 shares in the last quarter. Federated Hermes Inc. lifted its holdings in SOPHiA GENETICS by 16.4% during the second quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock worth $682,000 after acquiring an additional 31,000 shares in the last quarter. Akre Capital Management LLC grew its stake in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock valued at $11,529,000 after acquiring an additional 1,481,636 shares during the period. Dimensional Fund Advisors LP grew its stake in SOPHiA GENETICS by 24.7% in the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock valued at $148,000 after acquiring an additional 6,205 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS in the third quarter worth about $49,000. Institutional investors and hedge funds own 31.59% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. BTIG Research reaffirmed a “buy” rating and issued a $8.00 target price on shares of SOPHiA GENETICS in a research note on Monday, June 15th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $7.50.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.